Neo Biopharm ApS: Financial statements 2025
CVR: 42875708
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Neo Biopharm ApS (CVR 42875708) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -357,308 and a net result of DKK -271,403 compared with DKK 157,190 the year before. Equity in the 2025 report amounted to DKK 1,994,496. The solvency ratio was 100%.
- Gross Profit
- DKK -357,308
- Profit/Loss
- DKK -271,403
- Equity
- DKK 1,994,496
- Total Assets
- DKK 1,994,496
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -357K | -271K | 2M | - |
| 2024 | - | 206K | 157K | 2.3M | - |
| 2023 | - | 528K | 244K | 2.1M | - |
Official annual report
How creditworthy is Neo Biopharm ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Neo Biopharm ApS has published its annual report for 2024. Gross profit came to DKK 206,139, and the net result was DKK 157,190.
About Neo Biopharm ApS
Neo Biopharm ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Amirhossein Saadatirad and Jakob Juul Rasmussen. The company is owned by Maryam Badri. In 2025, the company reported a gross profit of DKK -357,308 and a net result of DKK -271,403 compared with DKK 157,190 the year before. Equity in the 2025 report amounted to DKK 1,994,496.